$67.67
6.30% yesterday
Nasdaq, Sep 23, 10:00 pm CET
ISIN
US61023L1089
Symbol
MNPR

Monopar Therapeutics Inc Stock price

$67.67
+37.25 122.45% 1M
+30.07 79.97% 6M
+45.67 207.59% YTD
+63.30 1,448.51% 1Y
+60.27 814.46% 3Y
+42.80 172.04% 5Y
-64.83 48.93% 10Y
-64.83 48.93% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
+4.01 6.30%
ISIN
US61023L1089
Symbol
MNPR
Industry

Key metrics

Basic
Market capitalization
$417.5m
Enterprise Value
$364.3m
Net debt
positive
Cash
$53.3m
Shares outstanding
6.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.0
Financial Health
Equity Ratio
91.3%
Return on Equity
-29.1%
ROCE
-36.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | -
EBIT
$-19.1m | $-16.0m
Net Income
$-17.3m | $-11.3m
Free Cash Flow
$-9.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-155.0% | -0.1%
Net Income
-143.1% | 29.7%
Free Cash Flow
-43.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.5
FCF per Share
$-1.6
Short interest
6.9%
Employees
15
Rev per Employee
$0.0
Show more

Is Monopar Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Monopar Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Monopar Therapeutics Inc forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Monopar Therapeutics Inc forecast:

Buy
85%
Hold
15%

Financial data from Monopar Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.82 4.82
58% 58%
-
- Research and Development Expense 14 14
221% 221%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -19 -19
155% 155%
-
Net Profit -17 -17
143% 143%
-

In millions USD.

Don't miss a Thing! We will send you all news about Monopar Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Monopar Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 11 hours ago
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67....
Neutral
GlobeNewsWire
about 11 hours ago
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (link), authored by leading Wilson disease physicians, entitle...
Positive
Investors Business Daily
9 days ago
Monopar Therapeutics unveiled promising results Monday from three key studies, leading the top 1% biotech stock to break out of a cup base.
More Monopar Therapeutics Inc News

Company Profile

Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Head office United States
CEO Chandler Robinson
Employees 15
Founded 2014
Website www.monopartx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today